留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

体质量控制与非酒精性脂肪性肝病: 来自中国人群的证据

杨晨露 赵欣宇 胡诗琪 蓝彦琦 冯宝玉 王丽

杨晨露, 赵欣宇, 胡诗琪, 蓝彦琦, 冯宝玉, 王丽. 体质量控制与非酒精性脂肪性肝病: 来自中国人群的证据[J]. 协和医学杂志, 2023, 14(1): 44-49. doi: 10.12290/xhyxzz.2022-0691
引用本文: 杨晨露, 赵欣宇, 胡诗琪, 蓝彦琦, 冯宝玉, 王丽. 体质量控制与非酒精性脂肪性肝病: 来自中国人群的证据[J]. 协和医学杂志, 2023, 14(1): 44-49. doi: 10.12290/xhyxzz.2022-0691
YANG Chenlu, ZHAO Xinyu, HU Shiqi, LAN Yanqi, FENG Baoyu, WANG Li. Weight Control and Non-alcoholic Fatty Liver Disease: Evidence from China[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(1): 44-49. doi: 10.12290/xhyxzz.2022-0691
Citation: YANG Chenlu, ZHAO Xinyu, HU Shiqi, LAN Yanqi, FENG Baoyu, WANG Li. Weight Control and Non-alcoholic Fatty Liver Disease: Evidence from China[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(1): 44-49. doi: 10.12290/xhyxzz.2022-0691

体质量控制与非酒精性脂肪性肝病: 来自中国人群的证据

doi: 10.12290/xhyxzz.2022-0691
基金项目: 

首都卫生发展科研专项 2022-1-2021

详细信息
    通讯作者:

    王丽, E-mail: liwang@ibms.pumc.edu.cn

  • 中图分类号: R-1;R181.3

Weight Control and Non-alcoholic Fatty Liver Disease: Evidence from China

Funds: 

The Capital Health Research and Development of Special 2022-1-2021

More Information
  • 摘要: 基于中国人群的临床试验及队列研究数据,本文系统总结了体质量/体质量指数(body mass index, BMI)水平及其变化在非酒精性脂肪性肝病(non-alcoholic fatty liver disease, NAFLD)预防及其不良结局发生风险中的意义。结果显示,BMI与NAFLD发生风险呈显著正相关;对于已发生NAFLD的人群,其基线BMI水平与NAFLD缓解率呈负相关,与死亡或肿瘤等不良结局发生风险呈非线性相关;BMI正常的瘦型NAFLD人群全因死亡、肝脏相关死亡、消化系统肿瘤与肥胖相关肿瘤的发生风险较超重或肥胖型NAFLD、瘦型非NAFLD人群升高。NAFLD人群基线BMI水平与其不良结局的关联性可能受其他代谢指标的影响。控制基线BMI后,虽然多数研究提示体质量减轻可降低NAFLD发生风险,但由于不同研究对BMI变化的评估方法与评估时间窗不同,目前对于如何控制体质量进行NAFLD预防尚未达成一致结论。对于已发生NAFLD的人群,有限的证据显示减重对不同不良结局发生风险产生不同的影响。未来需开展多中心队列研究和试验性研究,充分考虑NAFLD的异质性,针对不同特征人群制订个体化体质量控制策略。
    作者贡献:杨晨露负责论文撰写;王丽负责选题设计、论文修订;赵欣宇、胡诗琪、蓝彦琦、冯宝玉负责文献分析。
    利益冲突:所有作者均声明不存在利益冲突
  • 图  1  不同亚型男性新发NAFLD患者不良结局累积发生率[25]

    A.全因死亡;B.肿瘤;C.心血管疾病;D.慢性肾脏病 NAFLD:非酒精性脂肪性肝病

  • [1] Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes [J]. Hepatology, 2016, 64: 73-84. doi:  10.1002/hep.28431
    [2] Lee HW, Wong VW. Changing NAFLD Epidemiology in China [J]. Hepatology, 2019, 70: 1095-1098. doi:  10.1002/hep.30848
    [3] Byrne CD, Targher G. NAFLD as a driver of chronic kidney disease [J]. J Hepatol, 2020, 72: 785-801.
    [4] Byrne CD, Perseghin G. Non-alcoholic fatty liver disease: A risk factor for myocardial dysfunction? [J]. J Hepatol, 2018, 68: 640-642. doi:  10.1016/j.jhep.2017.12.002
    [5] Hagstrom H, Talback M, Andreasson A, et al. Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease [J]. J Hepatol, 2020, 73: 1023-1029. doi:  10.1016/j.jhep.2020.06.007
    [6] Wang Z, Zhao X, Chen S, et al. Associations Between Nonalcoholic Fatty Liver Disease and Cancers in a Large Cohort in China [J]. Clin Gastroenterol Hepatol, 2021, 19: 788-796. e4. doi:  10.1016/j.cgh.2020.05.009
    [7] Rinella M, Charlton M. The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health [J]. Hepatology, 2016, 64: 19-22.
    [8] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版) [J]. 实用肝脏病杂志, 2018, 21: 177-186. doi:  10.3969/j.issn.1672-5069.2018.02.007
    [9] European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease [J]. J Hepatol, 2016, 64: 1388-1402.
    [10] Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases [J]. Hepatology, 2018, 67: 328-357. doi:  10.1002/hep.29367
    [11] Chitturi S, Wong VW, Chan WK, et al. The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups [J]. J Gastroenterol Hepatol, 2018, 33: 86-98.
    [12] Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease [J]. Lancet, 2021, 397: 2212-2224. doi:  10.1016/S0140-6736(20)32511-3
    [13] Diehl AM, Day C. Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis [J]. N Engl J Med, 2017, 377: 2063-2072. doi:  10.1056/NEJMra1503519
    [14] Ye Q, Zou B, Yeo YH, et al. Global prevalence, inci-dence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis [J]. Lancet Gastroenterol Hepatol, 2020, 5: 739-752. doi:  10.1016/S2468-1253(20)30077-7
    [15] Baratta F, D'erasmo L, Bini S, et al. Heterogeneity of non-alcoholic fatty liver disease (NAFLD): Implication for cardiovascular risk stratification [J]. Atherosclerosis, 2022, 357: 51-59. doi:  10.1016/j.atherosclerosis.2022.08.011
    [16] Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD) [J]. Endocr Pract, 2022, 28: 528-562. doi:  10.1016/j.eprac.2022.03.010
    [17] Quek J, Chan KE, Wong ZY, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis [J]. Lancet Gastroenterol Hepatol, 2023, 8: 20-30. doi:  10.1016/S2468-1253(22)00317-X
    [18] Yi M, Chen RP, Yang R, et al. Increased prevalence and risk of non-alcoholic fatty liver disease in overweight and obese patients with Type 2 diabetes in South China [J]. Diabet Med, 2017, 34: 505-513. doi:  10.1111/dme.13174
    [19] Li L, Liu DW, Yan HY, et al. Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies [J]. Obes Rev, 2016, 17: 510-519. doi:  10.1111/obr.12407
    [20] Guan X, Zhang Q, Xing J, et al. Systolic Blood Pressure Mediates Body Mass Index and Non-alcoholic Fatty Liver Disease: A Population-Based Study [J]. Turk J Gastroenterol, 2021, 32: 458-465. doi:  10.5152/tjg.2021.20641
    [21] 霍艳蓓, 白亚娜, 张德生, 等. 金昌队列人群非酒精性脂肪肝发病的影响因素分析[J]. 中华流行病学杂志, 2021, 42: 493-498. doi:  10.3760/cma.j.cn112338-20200428-00668
    [22] 余馨妍, 赵奕, 宋筱筱, 等. 人体质量指数与非酒精性脂肪性肝病发生和消退的关系[J]. 浙江大学学报(医学版), 2014, 43: 546-552. doi:  10.3785/j.issn.1008-9292.2014.09.010
    [23] Wu J, He S, Xu H, et al. Non-alcoholic fatty liver disease incidence, remission and risk factors among a general Chinese population with a 6-year follow-up [J]. Sci Rep, 2018, 8: 7557. doi:  10.1038/s41598-018-25641-z
    [24] Lan Y, Lu Y, Li J, et al. Outcomes of subjects who are lean, overweight or obese with nonalcoholic fatty liver disease: A cohort study in China [J]. Hepatol Commun, 2022, 6: 3393-3405. doi:  10.1002/hep4.2081
    [25] 胡诗琪. 基于开滦队列的非酒精性脂肪性肝病亚型分类及其健康效应研究[D]. 北京: 中国医学科学院北京协和医学院, 2022.
    [26] 王珊, 张健, 张杰, 等. 体质量指数轨迹与新发非酒精性脂肪性肝病相关性的队列研究[J]. 中华肝脏病杂志, 2020, 28: 597-602. doi:  10.3760/cma.j.cn501113-20190629-00230
    [27] Tong C, Li Q, Kong L, et al. Sex-specific metabolic risk factors and their trajectories towards the non-alcoholic fatty liver disease incidence [J]. J Endocrinol Invest, 2022, 45: 2233-2245. doi:  10.1007/s40618-022-01848-w
    [28] Du S, Wang C, Jian W, et al. The impact of body weight gain on nonalcoholic fatty liver disease and metabolic syndrome during earlier and later adulthood [J]. Diabetes Res Clin Pract, 2016, 116: 183-191. doi:  10.1016/j.diabres.2016.04.047
    [29] Feng B, Chen S, Wang X, et al. Effect of cumulative body mass index exposure and long-term related change on incident non-alcoholic fatty liver disease [J]. Liver Int, 2022. doi:  10.1111/liv.15436.
    [30] Liu M, Wang J, Zeng J, et al. Association of NAFLD With Diabetes and the Impact of BMI Changes: A 5-Year Cohort Study Based on 18, 507 Elderly [J]. J Clin Endocrinol Metab, 2017, 102: 1309-1316. doi:  10.1210/jc.2016-3440
    [31] Zhang HJ, He J, Pan LL, et al. Effects of Moderate and Vigorous Exercise on Nonalcoholic Fatty Liver Disease: A Randomized Clinical Trial [J]. JAMA Intern Med, 2016, 176: 1074-1082. doi:  10.1001/jamainternmed.2016.3202
    [32] Hu S, Li X, Sun Y, et al. Short-term weight loss decreased the risk of chronic kidney disease in men with incident nonalcoholic fatty liver disease [J]. Obesity (Silver Spring), 2022, 30: 1495-1506. doi:  10.1002/oby.23459
    [33] 胡诗琪, 蓝彦琦, 吴寿岭, 等. 肥胖及其变化对中国华北新发NAFLD成年男性患者心血管疾病发病风险的影响[J]. 基础医学与临床, 2022, 42: 788-794. doi:  10.3969/j.issn.1001-6325.2022.05.015
    [34] Pan WH, Yeh WT. How to define obesity? Evidence-based multiple action points for public awareness, screening, and treatment: an extension of Asian-Pacific recommendations [J]. Asia Pac J Clin Nutr, 2008, 17: 370-374.
    [35] Arrese M, Arab JP, Barrera F, et al. Insights into Nonalcoholic Fatty-Liver Disease Heterogeneity [J]. Semin Liver Dis, 2021, 41: 421-434.
    [36] Dasarathy S, Dasarathy J, Khiyami A, et al. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study [J]. J hepatol, 2009, 51: 1061-1067. doi:  10.1016/j.jhep.2009.09.001
    [37] Wai JW, Fu C, Wong VW. Confounding factors of non-invasive tests for nonalcoholic fatty liver disease [J]. J Gastroenterol, 2020, 55: 731-741. doi:  10.1007/s00535-020-01686-8
    [38] Wong VW, Adams LA, De Lédinghen V, et al. Noninvasive biomarkers in NAFLD and NASH-current progress and future promise [J]. Nat Rev Gastroenterol Hepatol, 2018, 15: 461-478.
  • 加载中
图(1)
计量
  • 文章访问数:  2546
  • HTML全文浏览量:  564
  • PDF下载量:  217
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-12-03
  • 录用日期:  2023-01-09
  • 刊出日期:  2023-01-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!